[18F]DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor used for positron emission tomography (PET) imaging in small animals; it specifically targets PSMA-expressing tumors and shows high uptake in PIP tumors with minimal uptake in PSMA-negative FLU tumors; it exhibits favorable pharmacokinetics with rapid clearance from kidneys and bladder compared to tumor retention, achieving a high tumor-to-muscle ratio (20:1 at 120 minutes post-injection); due to its specific localization and imaging performance, [18F]DCFBC is a promising candidate for further investigation in PET imaging of prostate cancer.